ArticleScientific reports2025
Involvement of LncRNA FAF in chemotherapy-induced cardiotoxicity by mediating pyroptosis through modulation of the NLRP3-Caspase-1 signaling pathway.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cardiotoxin from Naja atra Activates the NLRP3/Caspase-1/GSDMD Pyroptosis Pathway to Induce Skin Tissue Injury.PLoS neglected tropical diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Purpose Chemotherapeutic agents, though highly effective in eliminating tumor cells, frequently cause varying degrees of myocardial injury. Doxorubicin (DOX) is a leading extensively used anthracycline-based chemotherapy agents. The present research sought to explore the role of lncRNA FAF in chemotherapy-induced cardiotoxicity and to elucidate its regulatory function via the NLRP3-Caspase-1 axis. Methods A rat model of DOX-induced cardiac toxicity was generated by administering the drug intraperitoneally, and cardiac function in rats was subsequently evaluated by echocardiography. We assessed morphological changes in rat myocardial tissue by hematoxylin-eosin and Masson staining, and measured the expression of biomarkers associated with cardiac damage, including LDH and CK-MB, using ELISA. Proteins involved in pyroptosis (GSDMD, NLRP3, and C-Caspase-1) were evaluated through TUNEL assay, immunohistochemical staining, and Western blot experiments. Cell viability was determined using the CCK-8 assay, while pyroptosis was inspected by flow cytometry, and lncRNA FAF expression was quantified by qRT-PCR. Results DOX administration induced cardiac dysfunction, myocardial tissue structural disorders and fibrosis, as well as heightened serum concentrations of LDH and CK-MB. In both animal and cell-based experiments, DOX treatment led to a decrease in lncRNA FAF expression in cardiac myocytes, accompanied by a significantly up-regulation of NLRP3, C-Caspase-1, and GSDND-N, thereby promoting cardiomyocyte pyroptosis. In contrast, high expression of lncRNA FAF enhanced cardiac myocytes viability, inhibited pyroptosis, and down-regulated the expression of NLRP3, C-Caspase-1, and GSDND-N. Importantly, these effects were reversed by treatment with the NLRP3 agonist nigericin or the pyroptosis agonist polyphyllin VI in cardiomyocytes treated with lncRNA FAF overexpression. Conclusion lncRNA FAF alleviates DOX-induced cardiomyocyte injury by enhancing cardiomyocyte viability and suppressing pyroptosis by targeting the NLRP3-Caspase-1 axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.